Oslo, Norway, December 29th, 2022 – AdjuTec Pharma AS, a privately held company developing antibiotic resistance breakers, turns the page of 2022 with an encouraging Christmas support from Oslo County of NOK 1.950mill. The funding will support optimization of the synthesis of our two lead compounds, APC148 and APC247. The program will define the optimal characteristics of the substances that will be used for microbiology testing as well as for testing in healthy volunteers in our clinical program. The R&D project will start first half of 2023 and Adjutec will collaborate closely with Kappa Solutions in Oslo, RISE at Södertälje in Sweden and researchers at the University of Oslo.
CEO Bjørn Klem recently presented Adjutec at the Biostock investor meetings in Lund and at the DNB Healthcare Conference in Oslo. These events were excellent opportunities for Adjutec to show-case the business opportunity of our antibiotic products.
“Adjutec continues to attract public funding to support our R&D program. The grant from Oslo County is a recognition of our drug development plans and supports our aim of building healthcare industry in Oslo in collaboration with local providers. It also strengthens the company attractiveness before our next capital raise that is planned first half of 2023 to fund clinical testing of our lead compound APC148” comments Bjørn Klem.
Full PR available here